Omicron Covid Variant

Eris or EG.5.1 was classified as a Covid variant on July 31 after UKHSA recorded its prevalence in the country due to rising cases internationally, particularly in Asia.

Pune-based Gennova Biopharmaceuticals Ltd on Tuesday said its mRNA COVID-19 booster vaccine against the Omicron variant, GEMCOVAC-OM, has received emergency use authorisation from the Drugs Controller General of India.

More than 1,300 samples of Omicron sub-variant XBB2.3 have been detected in India, while XBB.1.16 has become the dominant strain in the country, according to INSACOG data.

India has logged 10,158 fresh Covid-19 cases over the past 24 hours. It is believed that the Omicron subvariant, XBB.1.16 is driving the latest surge in the country.

The omicron subvariant XBB.1.16 is the main cause of the surge. According to the WHO, the subvariant and its spread in India are being monitored.

Amid a spurt in fresh Covid infections, 234 cases of XBB1.16.1 mutated sub-variant have been found in the country, according to INSACOG data.

The new Covid-19 variant, XBB.1.16 is responsible for the surge in cases in India. According to the Health Ministry data, India has reported a total of 5,880 covid cases in the last 24 hours.

Symptoms of this variant include fever that gradually climbs and lasts for 1-2 days, sore throat, bodily soreness, headaches and abdominal discomfort.

Fever, sore throat, body pain, headaches and abdominal discomfort are some of the symptoms of the XBB.1.16 variant.

The Union Health Ministry said on Thursday that the XBB.1.16 subvariant of Omicron might be the dominant virus strain in the country but there has been no reported increase in the rate of hospitalisation or death so far.

Rats collected in the study tested positive for alpha, delta and omicron variants of the SARS-CoV-2 virus.

Omicron and its sub-lineages continue to be the dominant coronavirus variants in India, Minister of State for Health Bharati Pravin Pawar told the Lok Sabha on Friday.

The Omicron subvariant XBB.1.5, the most transmissible Covid-19 subvariant so far, is spreading quickly across the United States and was predicted on Friday to become Europe's dominant strain in a matter of weeks.

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.

Four cases of Omicron subvariant BF.7 were detected in West Bengal, a health official said on Wednesday.

Eris or EG.5.1 was classified as a Covid variant on July 31 after UKHSA recorded its prevalence in the country due to rising cases internationally, particularly in Asia.

Pune-based Gennova Biopharmaceuticals Ltd on Tuesday said its mRNA COVID-19 booster vaccine against the Omicron variant, GEMCOVAC-OM, has received emergency use authorisation from the Drugs Controller General of India.

More than 1,300 samples of Omicron sub-variant XBB2.3 have been detected in India, while XBB.1.16 has become the dominant strain in the country, according to INSACOG data.

India has logged 10,158 fresh Covid-19 cases over the past 24 hours. It is believed that the Omicron subvariant, XBB.1.16 is driving the latest surge in the country.

The omicron subvariant XBB.1.16 is the main cause of the surge. According to the WHO, the subvariant and its spread in India are being monitored.

Amid a spurt in fresh Covid infections, 234 cases of XBB1.16.1 mutated sub-variant have been found in the country, according to INSACOG data.

The new Covid-19 variant, XBB.1.16 is responsible for the surge in cases in India. According to the Health Ministry data, India has reported a total of 5,880 covid cases in the last 24 hours.

Symptoms of this variant include fever that gradually climbs and lasts for 1-2 days, sore throat, bodily soreness, headaches and abdominal discomfort.

Fever, sore throat, body pain, headaches and abdominal discomfort are some of the symptoms of the XBB.1.16 variant.

The Union Health Ministry said on Thursday that the XBB.1.16 subvariant of Omicron might be the dominant virus strain in the country but there has been no reported increase in the rate of hospitalisation or death so far.

Rats collected in the study tested positive for alpha, delta and omicron variants of the SARS-CoV-2 virus.

Omicron and its sub-lineages continue to be the dominant coronavirus variants in India, Minister of State for Health Bharati Pravin Pawar told the Lok Sabha on Friday.

The Omicron subvariant XBB.1.5, the most transmissible Covid-19 subvariant so far, is spreading quickly across the United States and was predicted on Friday to become Europe's dominant strain in a matter of weeks.

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.

Four cases of Omicron subvariant BF.7 were detected in West Bengal, a health official said on Wednesday.